A Phase 4 interventional study of Yellow Fever vaccination (17 DD Biomanguinhos) in HIV Infections, sponsored by Oswaldo Cruz Foundation. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-30.
Sponsored by Oswaldo Cruz Foundation · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in HIV Infections with a site in Brazil — 12 open to participants now, 17 under way, 5 of them phase 3. HIV Infections · Brazil.
Among the 142 studies in HIV Infections with a site in Brazil, this one is the 51st largest by planned enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2017, is one of 21 in phase 4, reaches primary completion later than 1 of the 16 other live ones, and was the 110th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →12 of the 142 studies in HIV Infections with a site in Brazil are open now. Recruiting first, the newest first:
Oswaldo Cruz Foundation · Sites in Brazil
Ages 18+ · Men only · Healthy volunteers
Oswaldo Cruz Foundation · Sites in Brazil
Ages 18+ · Healthy volunteers
Oswaldo Cruz Foundation · Sites in Brazil
Ages 15+ · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Brazil, United States, Peru
Ages 18–70
Instituto Nacional de Cardiologia de Laranjeiras · Sites in Brazil
Ages 30–50 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 59 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 33 · Phase 3 45 · Phase 4 21
First in 1999; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 255 across the 116 interventional studies, 229 across the 22 observational. Of the 119 that completed or were terminated, 61 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 142 have an industry lead sponsor. The 10 most frequent:
Oswaldo Cruz Foundation is the lead sponsor of 42 studies on the registry; 7 are open to participants now.
Oswaldo Cruz Foundation has 8 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07584122Oswaldo Cruz FoundationImproving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro | 2026-12 |
| NCT04512456Instituto Nacional de Cardiologia de LaranjeirasCardiovascular Responses to Exercise in People Living With HIV/AIDS: Effects of Exercise Training | 2026-12-31 |
| NCT07500415Oswaldo Cruz FoundationDoxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 142 studies in HIV Infections with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 4 study to evaluate the immunogenicity and Safety of the 17DD Yellow Fever vaccine in HIV infected individuals, compared to non-HIV-infected individuals.
Main objective:
To compare the proportion of seroconversion and the geometric mean of neutralizing antibodies 30 days and 365 days after vaccine.
Secondary objectives:
To evaluate whether the titles of neutralizing antibodies are associated with CD4 lymphocyte counts, CD8 lymphocyte counts, CD4 nadir, HIV viral load and use of antiretroviral therapy. To assess the yellow fever vaccine viremia at day 10 after vaccine.To compare the incidence of adverse events in HIV-infected and non-HIV-infected individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 HIV positive adults with CD4 \> 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, \>500 cells/mm3). Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)
Biological: Yellow Fever vaccination (17 DD Biomanguinhos)
100 HIV negative adults. Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)
Biological: Yellow Fever vaccination (17 DD Biomanguinhos)
One intramuscular injection
Immunogenicity
Seroconversion
Time frame: 30 days after the vaccine
Immunogenicity
Neutralizing antibodies titers
Time frame: 30 days after the vaccine
Immunogenicity
Seroconversion
Time frame: 365 days after the vaccine
Immunogenicity
Neutralizing antibodies titers
Time frame: 365 days after the vaccine
Viremia
Yellow Fever vaccine viremia
Time frame: 7 days after the vaccine
Adverse events
Yellow Fever vaccine related adverse events
Time frame: up to 30 days after the vaccine
Immunogenicity
Neutralizing antibodies titles
Time frame: 5 years after the vaccine
Immunogenicity
Neutralizing antibodies titles
Time frame: 10 years after the vaccine
Plan to share: No
No publications or documents are linked to this record.
Started May 2017 (actual). Primary completion is estimated for Dec 2018, 19 months after the start.
Of 78 non-industry phase 4 interventional studies under HIV Infections, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 45. This study's planned 19 months is below that.
Counting every sponsor, half of 91 studies reached it within 35 months; a quarter within 23 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oswaldo Cruz Foundation